Cytokinetics Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cytokinetics stock.
View analyst ratings for Cytokinetics or view top-rated stocks.

Wall Street analysts have given Cytokinetics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cytokinetics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cytokinetics saw a increase in short interest during the month of July. As of July 30th, there was short interest totaling 11,920,000 shares, an increase of 32.4% from the July 15th total of 9,000,000 shares. Based on an average trading volume of 1,810,000 shares, the short-interest ratio is currently 6.6 days.
View Cytokinetics' Short Interest.

Cytokinetics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Cytokinetics.

Cytokinetics, Incorporated (NASDAQ:CYTK) issued its quarterly earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.66) by $0.20. The biopharmaceutical company earned $2.84 million during the quarter, compared to analysts' expectations of $5.68 million. Cytokinetics had a negative net margin of 269.48% and a negative trailing twelve-month return on equity of 179.39%.
View Cytokinetics' earnings history.

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CYTK shares have increased by 178.4% and is now trading at $33.49.
View which stocks have been most impacted by COVID-19.

Cytokinetics issued an update on its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $23 million-$28 million, compared to the consensus revenue estimate of $28.07 million.

11 analysts have issued 1-year price targets for Cytokinetics' shares. Their forecasts range from $16.00 to $58.00. On average, they expect Cytokinetics' stock price to reach $43.09 in the next year. This suggests a possible upside of 28.7% from the stock's current price.
View analysts' price targets for Cytokinetics or view top-rated stocks among Wall Street analysts.

16 employees have rated Cytokinetics CEO Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among Cytokinetics' employees.

Some companies that are related to Cytokinetics include Dr. Reddy's Laboratories (RDY), CureVac (CVAC), Bausch Health Companies (BHC), Grifols (GRFS), Teva Pharmaceutical Industries (TEVA), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), Biohaven Pharmaceutical (BHVN), Mirati Therapeutics (MRTX), Evotec (EVTCY), Jazz Pharmaceuticals (JAZZ), BridgeBio Pharma (BBIO), Mawson Infrastructure Group (WIZP), Sarepta Therapeutics (SRPT) and Arrowhead Pharmaceuticals (ARWR).
View all of CYTK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (16.25%), FMR LLC (10.16%), Vanguard Group Inc. (5.66%), State Street Corp (5.09%), Wasatch Advisors Inc. (3.11%) and Integral Health Asset Management LLC (1.68%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Ching Jaw, David Cragg, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Robert I Blum, Sandford D Smith, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga.
View institutional ownership trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., BlackRock Inc., Goldman Sachs Group Inc., Vanguard Group Inc., Marshall Wace LLP, Marshall Wace LLP, Bank of New York Mellon Corp, and Point72 Asset Management L.P.. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Ching Jaw, David Cragg, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Robert I Blum, Sandford D Smith, and Santo J Costa.
View insider buying and selling activity for Cytokinetics or view top insider-selling stocks.

CYTK stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Commodore Capital LP, Logos Global Management LP, Integral Health Asset Management LLC, Squarepoint Ops LLC, State Street Corp, Northern Trust Corp, and Bank of America Corp DE. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Cytokinetics or or view top insider-buying stocks.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CYTK stock can currently be purchased for approximately $33.49.

Cytokinetics has a market capitalization of $2.80 billion and generates $55.83 million in revenue each year. The biopharmaceutical company earns $-127,290,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis.

Cytokinetics employs 184 workers across the globe.

Cytokinetics was founded in 1997.

The official website for Cytokinetics is www.cytokinetics.com.

Cytokinetics is headquartered at 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at (650) 624-3000 or via email at [email protected]